Business Context and Reporting Period
This Form 8-K filing by Neumora Therapeutics, Inc. (NMRA) was submitted on May 16, 2025, reporting an event that occurred on May 14, 2025. The Company is a Delaware corporation with its principal executive offices in Watertown, Massachusetts, and its common stock trades on The Nasdaq Global Select Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on regulatory compliance regarding stock listing standards rather than financial performance metrics.
Material Changes
On May 14, 2025, the Company received written notice from Nasdaq indicating non-compliance with Listing Rule 5450(a)(1) due to failure to maintain the $1.00 minimum bid price requirement for continued listing. This represents a material change in the Company's listing status, triggering a compliance period.
Guidance, Outlook, and Risks
- Compliance Period: The Company has 180 calendar days, until November 10, 2025, to regain compliance. The closing bid price must meet or exceed $1.00 per share for ten consecutive business days within this window.
- Remediation Strategy: The Company intends to consider options to resolve the non-compliance, including a reverse stock split. The Board has approved amendments to the Certificate of Incorporation for a reverse stock split at a ratio between 1-for-5 and 1-for-30, subject to stockholder approval.
- Stockholder Vote: Stockholders will vote on the reverse stock split proposal at the Annual Meeting on May 28, 2025.
- Delisting Risk: If compliance is not achieved by the deadline, the Company may be eligible to transfer to The Nasdaq Capital Market, subject to meeting specific market value and listing standards. Failure to regain compliance or transfer could result in delisting.
- Uncertainty: There is no assurance that stockholders will approve the reverse stock split, that the Company will regain compliance, or that Nasdaq will grant an appeal if delisting is initiated.
Investor Verification Checklist
- Verify the outcome of the stockholder vote on the reverse stock split at the May 28, 2025 Annual Meeting.
- Monitor the daily closing bid price of NMRA common stock to track progress toward the $1.00 threshold.
- Review the Definitive Proxy Statement (Schedule 14A) filed on April 29, 2025, for details on the reverse stock split ratio and terms.
- Watch for future Nasdaq communications regarding the Company's compliance status or potential transfer to The Nasdaq Capital Market.